Home > D. General pathology > Pathogenic agents > sevelamer
sevelamer
Wednesday 18 May 2016
| WP |
Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption.
Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is currently marketed by Sanofi under the trade names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
Image
https://twitter.com/pwraess/status/713151761951789056
Pathology
digestove mucosal injury (24061514)
References
Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. Swanson BJ, Limketkai BN, Liu TC, Montgomery E, Nazari K, Park JY, Santangelo WC, Torbenson MS, Voltaggio L, Yearsley MM, Arnold CA. Am J Surg Pathol. 2013 Nov;37(11):1686-93. doi : 10.1097/PAS.0b013e3182999d8d PMID: 24061514
